Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation June 17, 2020
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc. May 26, 2020
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants May 21, 2020
ContraFect Announces Dr. Roger J. Pomerantz, Chief Executive Officer and Chairman, Invited as Keynote Speaker and Presenter in Maxim’s Infectious Disease Virtual Conference April 21, 2020
ContraFect Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update March 18, 2020
